Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients

Journal of International Medical Research

Volumn 33, Issue 4, 2005, Pages 406-416

  Gabutti, Giovanni ^a,b,c,d,e   Guido, M ^a   Durando, P ^b   De Donno, A ^a   Quattrocchi, M ^a   Bacilieri, S ^b   Ansaldi, F ^b   Cataldini, F ^c   Chiriaco P G ^d   De Simone, M ^c   Minniti, S ^d   Sticchi, L ^b   Gasparini, R ^b  

^a UNIVERSITY OF SALENTO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Gallipoli Hospital   (Italy)

^d A Perrino Hospital   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

CD4+ T lymphocytes; Human immunodeficiency virus; Human immunodeficiency virus 1 RNA; Immunogenicity; Influenza vaccine; Safety

Indexed keywords

AGRIPPAL S1; ANTIRETROVIRUS AGENT; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE REACTION; ITALY; LYMPHOCYTE COUNT; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS STRAIN;

EID: 23044486311     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000503300406     Document Type: Article

References (38)

1. Vu T, Farish S, Jenkins M, Kelly H: A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20: 1831-1836.
2. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA for the Advisory Committee on Immunization Practices: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52: 1-34.
3. Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P, et al: Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002; 20 (Suppl 5): B5O-B54.
4. Evans KD, Kline MW: Prolonged influenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995; 14: 332-334.
5. Moss RB, Wallace MR, Lanza P, Giermakowska W, Jensen FC, Theofan G, et al: In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 1998; 5: 308-312.
6. Neuzil KM, Reed GW, Mitchel EF, Jr, Griffin MR: Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901-907.
7. Radwan HM, Cheeseman SH, Lai KK, Ellison III RT: Influenza in human immuno-deficiency virus-infected patients during the 1997 - 1998 influenza season. Clin Infect Dis 2000; 31: 604-606.
8. Lin JC, Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161: 441-446.
9. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E: Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20 (Suppl 5): B29-B32.
10. Joint Committee on Vaccination and Immunisation: Immunisation Against Infectious Disease 1992. London: HMSO, 1992.
11. Health Council of The Netherlands: Committee on Influenza Vaccination: Influenza Vaccination: Season 1993 - 1994. Publication no. 1993/16. The Hague: Health Council of The Netherlands, 1993.
12. Iorio AM, Francisci D, Camilloni B, Stagni G, De Martino M, Toneatto D, et al: Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003; 21: 3629-3637.
13. Couch RB: Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999; 28: 548-551.
14. Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, et al: Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181: 522-531.
15. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al: Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17: 135-140.
16. Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-2680.
17. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMRW Recomm Rep 1992; 41 (RR-17): 1-19.
18. Dowle WR, Kendal AP, Noble GR: Influenza viruses. In: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 5th edn (Lennette EM, Schmidt NJ, eds). Washington, DC: American Public Health Association, 1979; pp585-590.
19. Committee for Proprietary Medicinal Product (CPMP): Note for Guidance on Harmonization of Requirements for Influenza Vaccines (Revision). 1997; CPMP/BWP/214/96.
20. o luglio 2002.
21. Sorvillo FJ, Nahlen BL: Influenza immunization for HIV-infected persons in Los Angeles. Vaccine 1995; 13: 337-380.
22. Centers for Disease Control and Prevention - recommendations of the Immunization Practices Advisory Committee (ACIP): Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. MMWR Morb Mortal Wkly Rep 1986; 35: 595-598/603-606.
23. Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW for the Adult and Adolescent Spectrum of HIV Disease Investigators: Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000; 14: 2781-2785.
24. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R: Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18: 3040-3049.
25. Amendola A, Boschini A, Colzani D, Anselmi G, Oltolina A, Zucconi R, et al: Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001; 65: 644-648.
26. de Carvalho AP, Dutra LC, Tonelli E: Influenza vaccination in HIV infected children: immunologic and viral load changes (in Portuguese). J Pediatr (Rio J) 2003; 79: 29-40.
27. Zuccotti GV, Zenga A, Durando P, Massone L, Bruzzone B, Sala D, et al: Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. J Int Med Res 2004; 32: 492-499.
28. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182: 1727-1737.
29. O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, et al: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86: 1082-1089.
30. Rosok B, Voltersvik P, Bjerknes R, Axelsson M, Haaheim LR, Asjo B: Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals. Clin Exp Immunol 1996; 104: 203-207.
31. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D: Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28: 541-547.
32. Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430-433.
33. Skiest DJ, Machala T: Comparison of the effects of acute influenza infection and influenza vaccination on HIV viral load and CD4 cell counts. J Clin Virol 2003; 26: 307-315.
34. Iorio AM, Alatri A, Francisci D, Preziosi R, Neri M, Donatelli I, et al: Immunogenicity of influenza vaccine (1993 - 94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997; 15: 97-102.
35. Tasker SA, O'Brien WA, Treanor JJ, Weiss PJ, Olson PE, Kaplan AH, et al: Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998; 16: 1039-1042.
36. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al: Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12: F217-F223.
37. Pinto LA, Blazevic V, Anderson SA, Venzon DJ, Trubey CM, Rowe T, et al: Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis 2001; 183: 1000-1008.
38. Banic S, Koren S, Tomazic J, Vidmar L, Ihan A, Poljak M, et al: Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol 2001; 45: 39-44.